https://www.eurekalert.org/news-releases/1005570
0
0
11/4/23 at 2:01am
Organization
EurekAlert
59 words
0
Comments
<ul>
<li>Results from the phase 3 SCORED trial indicate that sotagliflozin protects kidney and heart health in individuals with type 2 diabetes and chronic kidney disease.</li>
<li>Results from the study will be presented at ASN Kidney Week 2023 November 1&…
You are the first to view
Create an account
or login to join the discussion